$305mn Bet on Peptides Signals Shift in Cancer

Parabilis raises funding from RA Capital, Fidelity and Janus to advance intracellular peptide drugs into late-stage trials

23 Feb 2026

Parabilis Medicines has raised $305mn in one of the largest recent private financings for peptide-based cancer drugs, highlighting investor interest in therapies designed to reach targets inside cancer cells.

The round was led by RA Capital Management, with participation from Fidelity Management & Research Company and Janus Henderson Investors. The size of the financing stands out in a market where private biotech funding has been more selective, particularly for companies developing novel drug platforms.

Parabilis is developing peptide medicines engineered to enter cells and block proteins that drive tumour growth. Such intracellular targets have often proved difficult to reach with conventional small-molecule drugs or antibody therapies, which typically act outside cells or on their surface.

The company’s lead candidate, zolucatetide, is being prepared for a registrational trial in desmoid tumours, a rare and locally aggressive cancer. Parabilis is also evaluating the drug in additional tumour types. Success in late-stage trials would be required before seeking regulatory approval.

Beyond its lead programme, the group plans to use the proceeds to expand its peptide discovery platform. The company says the platform is designed to create precision molecules that can cross cell membranes and disrupt disease processes from within. Investors appear to be backing not only zolucatetide but also the potential for a broader pipeline generated from the same technology.

The participation of crossover investors such as Fidelity and Janus Henderson, which often invest in companies approaching clinical inflection points, may signal expectations of significant trial data in the coming years. Their involvement can also precede a public offering, depending on market conditions and clinical progress.

Peptide therapeutics have attracted renewed attention as oncology drug development becomes more crowded and companies seek new biological pathways to differentiate their products. However, clinical risks remain. Data will need to demonstrate both safety and clear benefit, and manufacturing complex peptides at scale can present technical challenges.

The latest financing provides Parabilis with capital to advance its programmes through critical stages of development. Whether intracellular peptides become a broader force in oncology will depend on the outcome of forthcoming trials and regulatory review.